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Aims Guidelines do not recommend to take pattern of atrial fibrillation (AF) into account for the indication of anticoagu-
lation (AC). We assessed AF pattern and the risk of cardiovascular events during 2-years of follow-up.
...................................................................................................................................................................................................
Methods
and results
We categorized AF as paroxysmal, persistent, or permanent in 29 181 patients enrolled (2010–15) in the Global
Anticoagulant Registry In the FIELD of AF (GARFIELD-AF). We used multivariable Cox regression to assess the
risks of stroke/systemic embolism (SE) and death across patterns of AF, and whether this changed with AC on out-
comes. Atrial fibrillation pattern was paroxysmal in 14 344 (49.2%), persistent in 8064 (27.6%), and permanent
6773 (23.2%) patients. Median CHA2DS2-VASc, GARFIELD-AF, and HAS-BLED scores assessing the risk of stroke/
SE and/or bleeding were similar across AF patterns, but the risk of death, as assessed by the GARFIELD-AF risk cal-
culator, was higher in non-paroxysmal than in paroxysmal AF patterns. During 2-year follow-up, after adjustment,
non-paroxysmal AF patterns were associated with significantly higher rates of all-cause death, stroke/SE, and new/
worsening congestive heart failure (CHF) than paroxysmal AF in non-anticoagulated patients only. In anticoagulated
patients, a significantly higher risk of death but not of stroke/SE and new/worsening CHF persisted in non-
paroxysmal compared with paroxysmal AF patterns.
...................................................................................................................................................................................................
Conclusion In non-anticoagulated patients, non-paroxysmal AF patterns were associated with higher risks of stroke/SE, new/worsening
HF and death than paroxysmal AF. In anticoagulated patients, the risk of stroke/SE and new/worsening HF was similar
across all AF patterns. Thus AF pattern is no longer prognostic for stroke/SE when patients are treated with anticoagulants.
...................................................................................................................................................................................................
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Introduction
Patient characteristics included in the CHA2DS2-VASc score are im-
portant for risk stratification. Current guidelines in atrial fibrillation
(AF) recommend this score when deciding whether anticoagulant
therapy should be given for stroke prevention in patients with AF.1,2
The temporal pattern of AF, expressed as type of AF, has shown con-
flicting results with regard to its impact of stroke risk.3–5
The Global Anticoagulant Registry in the FIELD of AF (GARFIELD-
AF) is a multinational prospective registry of more than 50 000
patients with newly diagnosed AF and at least one additional risk fac-
tor for stroke.6,7 We used data from GARFIELD-AF to compare the
risk of stroke or death in patients with different types of AF, particu-
larly to assess the risk conferred by paroxysmal vs. other patterns,
and to evaluate whether the risk differed with the use of anticoagula-
tion (AC). In this report, the patients with at least 2-year follow-up
from the first four cohorts of GARFIELD-AF were evaluated.
Methods
GARFIELD-AF is a multinational registry of adults aged 18 years or more
with non-valvular AF and with at least one additional risk factor for
stroke, as judged by the investigator. Atrial fibrillation was diagnosed
(according to standard local procedures) within 6 weeks before enrol-
ment. Risk factors were not pre-specified in the protocol and were not
limited to the components of existing risk stratification schemes. Patients
with a transient and reversible cause of non-valvular AF and those for
whom follow-up was not possible were excluded. To minimize recruit-
ment bias, investigator sites were selected randomly from representative
care settings in each participating country, and consecutive eligible con-
senting patients were enrolled.6,7 Informed consent was obtained from all
study participants, and the study was approved by research Ethics
Committee and Institutional Review Boards.
Collection of follow-up data occurred at 4-month intervals up to
24 months. Outcome measures included clinical events, therapy persis-
tence, and healthcare utilization. The incidences of stroke/systemic em-
bolism (SE), death (cardiovascular and non-cardiovascular), heart failure
(HF) (occurrence or worsening), and bleeding (severity and location)
were recorded. Data for this report were extracted from the study data-
base in October 2017.
At baseline, investigators collected data on patient demographics,
medical history, care setting, type of AF (also collected during follow-up),
and antithrombotic treatment [vitamin K antagonists (VKA), non-vitamin
K antagonist oral anticoagulants, and antiplatelet (AP) treatment]. Data
on components of the CHA2DS2-VASc and HAS-BLED risk stratification
schemes were used to assess the risks of stroke and bleeding, retrospec-
tively. HAS-BLED scores were calculated excluding fluctuations in the
International Normalized Ratio. In addition, the risks of death, stroke/sys-
temic embolism (SE), and major bleeding were estimated at baseline with
the recently described GARFIELD-AF risk calculator.8
For patients with new (unclassified) AF at baseline, the type of AF was
assessed by the investigator within 150 days of enrolment. If the AF type
could not be assessed at 5 months, the patient was not included in the
analysis. The definition of AF types are according to the European Society
of Cardiology guidelines.1 Paroxysmal AF lasts no more than 7 days and is
self-terminating or is cardioverted within the 7-day window. Persistent
AF lasts longer than 7 days and includes episodes that are terminated by
drug or direct current cardioversion after 7 days. When no rhythm con-
trol strategies are pursued and AF is a continuing condition, the AF is
permanent.
Study outcomes and definitions
Clinical endpoints of the study were: (i) stroke/SE, (ii) major bleeding, (iii)
all-cause mortality, (iv) cardiovascular mortality, (v) non-cardiovascular
mortality, (vi) new acute coronary syndromes (ACS), and (vii) new or
worsening HF at 2-year follow-up.
Oral anticoagulants (OAC) included VKAs, direct factor Xa inhibitors,
and direct thrombin inhibitors. Antiplatelet therapy included: aspirin,
adenosine diphosphate receptor antagonists (P2Y12 inhibitors) or both.
Vascular disease included peripheral artery disease or coronary artery
disease with ACS. Chronic kidney disease was classified according to
National Kidney Foundation guidelines into two groups: moderate-to-
severe (stages 3–5), or mild (stages 1 and 2) or none.9 Heart failure at
baseline was defined as current/prior history of congestive heart failure
(CHF) or left ventricular ejection fraction (LVEF) of <40%.
Data were collected using an electronic case report form and were ex-
amined for completeness and accuracy by the coordinating centre
(Thrombosis Research Institute, London, UK). In accordance with the
study protocol, 20% of all data submitted electronically were monitored
against source documentation.
Ethics
The registry is being conducted in accordance with the principles of the
Declaration of Helsinki, local regulatory requirements, and the International
Conference on Harmonisation–Good Pharmacoepidemiological and
Clinical Practice guidelines.
Statistical analysis
Baseline patient characteristics were presented for the three AF catego-
ries (paroxysmal, persistent, or permanent), classified by the investigators
within the first 150 days of enrolment. Continuous variables were
expressed as median [interquartile range (IQR)] or mean [standard devia-
tion (SD)] and compared across the three AF categories using the
Kruskall–Wallis test. Categorical variables were presented as frequencies
(percentages) and were compared using the Pearson v2 test or exact test
when appropriate.
Clinical outcomes were compared between patients with each type of
AF. Occurrence of major clinical outcomes was expressed as person-
time event rates (per 100 person-years) and 95% confidence intervals
(CIs). Person-year rates were estimated using a Poisson model with the
number of events as the dependent variable and the log of time as an off-
set, i.e., a covariate with a known coefficient of 1. Only the first occur-
rence of events was taken into account. Hazard ratios (HRs) were
estimated using a proportional hazards Cox model. The proportional
What’s new?
• The relationship between atrial fibrillation (AF) pattern and
the risk of cardiovascular events is based on the real-world
prospective data collected during 2-years of follow-up in newly
diagnosed AF patients from the Global Anticoagulant Registry
In the FIELD of AF (GARFIELD-AF) registry.
• The GARFIELD-AF risk calculator showed a continuum of risk
for death as evidenced by a gradual increase in the risk score
across all three AF patterns.
• The novelty is that in anticoagulated patients, the risk of
stroke/systemic embolism was similar across AF patterns.
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hazard assumption was assessed visually using plots of the cumulative haz-
ard function. The following variables were included in the Cox model:
age groups (<65, 65–69, 70–74, >_75 years), gender, race (Caucasian/
Hispanic/Latino, Asian, other race—including Afro-Caribbean, mixed/
other, and unwilling to declare/not recorded), smoking (no, ex-smoker,
current), diabetes mellitus, hypertension, previous stroke/transient
ischaemic attack/SE, history of bleeding, HF, vascular disease, moderate-
to-severe renal disease, anticoagulant treatment, and heavy alcohol con-
sumption (only in the model for bleeding). Data analyses were performed
with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Of the 39 871 patients included in GARFIELD-AF, 22 805 patients had a
known type of AF, and 17 786 patients had new AF of unclassified type
(Supplementary material online, Figure S1). Of the 17 786 patients with
AF of unknown type, 7096 were classified by the investigator within the
first 150 days of enrolment (median 35 days, interquartile range 8–
90 days), bringing the total number of patients with a known type of AF
to 29 181. Of these patients, 14 344 (49.2%) had paroxysmal, 8064
(27.6%) persistent, and 6773 (23.2%) permanent AF.
Compared to patients with other AF types, those with paroxysmal
AF had a slightly lower body mass index, were less likely to have HF
or a LVEF <40%, but they were as likely to have history of stroke,
transient ischaemic attack, carotid artery occlusive disease, or ACS.
Median CHA2DS2-VASc and HAS-BLED scores were similar in all
three AF categories, but patients with permanent AF were more
likely to be >_75 years of age (Table 1). The estimated risks of stroke/
SE and major bleeding, as assessed with the GARFIELD-AF calculator,
were similar in all three AF categories, but the estimated risk of death
in patients with persistent and permanent AF patients was numeri-
cally higher than in patients with paroxysmal AF.
Antithrombotic therapy
Patients with paroxysmal AF were less likely to receive anticoagulant
therapy (with or without AP agents) than those with persistent or
permanent AF, and more likely to receive AP agents alone or no
antithrombotic treatment (Figure 1). Patients with permanent AF
were less likely to be treated by cardiologists and in a hospital than
patients in the other two categories of AF.
Among patients without vascular disease, 7463 (29.9%) were pre-
scribed with AP therapy. Among patients with vascular disease, 2462
(59.3%) were prescribed with AP therapy.
Cardiovascular outcomes
At 2-year follow-up, the rates of death (both cardiovascular and non-
cardiovascular mortality), stroke/SE, stroke, and new or worsening
HF were higher in patients with persistent and permanent AF than in
patients with paroxysmal AF (Table 2). The rates of these endpoints
were all significantly higher in patients with permanent AF compared
with paroxysmal AF. The same was true for the comparison of persis-
tent AF vs. paroxysmal AF, except for the risk of stroke/SE that was
non-significantly higher in persistent AF. Finally, no significant differen-
ces were observed for the rates of major bleeding and myocardial in-
farction/ACS across patients with the different AF types (Table 2).
After adjustment for age, gender, race, smoking, diabetes, hyperten-
sion, stroke/transient ischaemic attack, history of bleeding, cardiac
failure, vascular disease, moderate-to-severe chronic kidney disease,
and anticoagulant treatment at baseline, permanent AF was signifi-
cantly associated with a higher risk of stroke/SE, ischaemic stroke,
new or worsening HF, all-cause death, cardiovascular, and non-
cardiovascular death compared with paroxysmal AF subgroup.
Persistent AF was significantly associated with higher risk of new or
worsening HF, all-cause death, cardiovascular, and non-cardiovascular
death compared with paroxysmal AF subgroup (Figure 2). Full details
of the crude and adjusted rates for all major events, and their compo-
nents, are provided in Supplementary material online, Table S1.
With regard to HF, only few patients had undergone echocardiog-
raphy. The available data show that 5.7% of the patients in paroxys-
mal AF had reduced LV function, patients in persistent AF: 12.4%, and
patients in permanent AF: 13.1%.
Interactions between anticoagulant
therapy and cardiovascular outcomes
The analysis was repeated to determine whether the observed risks
were changed with anticoagulant treatment. There was a significant
interaction between type of AF and anticoagulant therapy for the
endpoints of stroke/SE, ischaemic stroke and new or worsening HF
in the whole population, with higher risks in non-paroxysmal AF in
non-anticoagulated patients only. The interaction for death was not
statistically significant (Figure 3). In anticoagulated patients, there
were no differences in the risks for any event between patients in the
paroxysmal and persistent or permanent AF groups, except for the
risk of death, which was significantly higher in non-paroxysmal com-
pared with paroxysmal AF.
We also performed a sensitivity analysis of the interaction in the
population of patients with a CHA2DS2-VASc score >_2. This analysis
confirmed the existence of a significant interaction for stroke/SE,
ischaemic stroke and new/worsening HF, with higher risks in non-
paroxysmal AF in non-anticoagulated patients only (Figure 4). The in-
teraction for death was not statistically significant irrespective of
stroke risk. In anticoagulated patients, there were no differences in
the risks for any event between patients in the paroxysmal and per-
sistent or permanent AF groups, except for the risk of death, which
was significantly higher in non-paroxysmal compared with paroxys-
mal AF. In low-risk patients (CHA2DS2-VASc Score 0 or 1), the rate
of events was too low to conduct meaningful sensitivity analyses.
Discussion
Our principal finding is that persistent and permanent AF are associ-
ated with a higher risk of stroke/SE, death, and new or worsening HF
than paroxysmal AF, even after adjustment for a large variety of clini-
cal features. The second important finding is that the increased risk of
all major adverse events was only apparent in the subgroup of
patients who was not prescribed anticoagulant therapy. In the antico-
agulated subgroup, there was no difference in the risks of stroke/SE
and new or worsening HF in paroxysmal compared with non-
paroxysmal forms of AF. However, an excess risk of death persisted
with AC in non-paroxysmal forms of AF, though at a lower level than
observed in the non-anticoagulated subgroup of patients.
This is in line with the findings of most published reports derived
from secondary analyses of large-scale clinical trials, registries or
AF patterns, anticoagulation, and outcome 3
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Table 1 Baseline characteristics
Paroxysmal
(N514 344)
Persistent
(N5 8064)
Permanent
(N56773)
P-value
Sex, n (%) <0.0001
Male 7577 (52.8) 4796 (59.5) 3833 (56.6)
Female 6767 (47.2) 3268 (40.5) 2940 (43.4)
Age, median (IQR), years 70.0 (61.0; 77.0) 70.0 (62.0; 77.0) 74.0 (66.0; 80.0) <0.0001
Age group, n (%) <0.0001
<65 years 4770 (33.3) 2464 (30.6) 1438 (21.2)
65–74 years 4747 (33.1) 2754 (34.2) 2110 (31.2)
>_75 years 4827 (33.7) 2846 (35.3) 3225 (47.6)
Ethnicity, n (%) <0.0001
Caucasian 8375 (60.2) 4830 (61.0) 4854 (73.0)
Hispanic/Latino 775 (5.6) 485 (6.1) 699 (10.5)
Asian (not Chinese) 3835 (27.6) 2244 (28.4) 742 (11.2)
Chinese 693 (5.0) 237 (3.0) 221 (3.3)
Afro-Caribbean/Mixed/Other 240 (1.7) 117 (1.5) 130 (2.0)
Vital measures
Body mass index, median (IQR), kg/m2 26.0 (24.0–30.0) 27.0 (24.0–31.0) 28.0 (24.0–31.0) <0.0001
Pulse, median (IQR), b.p.m. 80.0 (68.0–103.0) 88.0 (74.0–105.0) 84.0 (72.0–100.0) <0.0001
Systolic BP, median (IQR), mm Hg 130.0 (120.0–145.0) 130.0 (120.0–144.0) 134.0 (120.0–145.0) <0.0001
Diastolic BP, median (IQR), mmHg 80.0 (70.0-86.0) 80.0 (70.0–90.0) 80.0 (70.0–89.0) <0.0001
Left ventricular ejection fraction, n (%) <0.0001
<40% 498 (5.7) 645 (12.4) 445 (13.1)
>_40% 8227 (94.3) 4557 (87.6) 2943 (86.9)
Care setting specialty at diagnosis, n (%) <0.0001
Cardiology 9945 (69.3) 5516 (68.4) 3521 (52.0)
Geriatrics 47 (0.3) 29 (0.4) 37 (0.6)
Internal medicine 2411 (16.8) 1389 (17.2) 1523 (22.5)
Neurology 307 (2.1) 86 (1.1) 132 (2.0)
Primary care/general practice 1634 (11.4) 1044 (13.0) 1560 (23.0)
Care setting location at diagnosis, n (%) <0.0001
Anticoagulation clinic/thrombosis centre 68 (0.5) 56 (0.7) 96 (1.4)
Emergency room 1681 (11.7) 813 (10.1) 548 (8.1)
Hospital 8551 (59.6) 4843 (60.1) 3447 (50.9)
Office 4044 (28.2) 2352 (29.2) 2682 (39.6)
Medical history, n (%)
Congestive heart failure 2202 (15.4) 2033 (25.2) 1649 (24.4) <0.0001
Coronary artery disease 2904 (20.3) 1514 (18.8) 1469 (21.7) <0.0001
Acute coronary syndromes 1328 (9.3) 669 (8.3) 663 (9.8) 0.0048
Carotid occlusive disease 450 (3.2) 216 (2.7) 255 (3.8) 0.0007
Pulmonary embolism/deep vein thrombosis 321 (2.2) 193 (2.4) 212 (3.1) 0.0004
Coronary artery bypass graft 398 (2.8) 233 (2.9) 209 (3.1) 0.4266
History of stroke 1182 (8.3) 581 (7.2) 572 (8.5) 0.0074
History of transient ischaemic attack 639 (4.5) 312 (3.9) 385 (5.7) <0.0001
History of systemic embolism 87 (0.6) 65 (0.8) 53 (0.8) 0.1506
History of bleeding 363 (2.5) 204 (2.5) 211 (3.1) 0.0318
History of hypertension 10 819 (75.5) 6157 (76.5) 5300 (78.4) <0.0001
Hypercholesterolaemia 6019 (43.0) 3197 (40.9) 2760 (41.6) 0.0055
Diabetes mellitus 2911 (20.3) 1797 (22.3) 1574 (23.2) <0.0001
Hyperthyroidism 234 (1.7) 140 (1.8) 122 (1.8) 0.6446
Hypothyroidism 856 (6.1) 366 (4.6) 443 (6.6) <0.0001
Cirrhosis 59 (0.4) 58 (0.7) 40 (0.6) 0.0081
Vascular disease 2082 (14.5) 1058 (13.1) 1013 (15.0) 0.0022
Continued
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meta-analyses, which consistently show that the risk of stroke/SE
(and also death in a few studies) was higher in non-paroxysmal
forms of AF compared with paroxysmal AF.3,4,10–16 The worse
prognosis with non-paroxysmal AF is thought to be linked to the
higher risk profile of these patients. In a few reports, the risk of
stroke/SE was found to be similar across all patterns of AF, leading
the authors to conclude that the decision to anticoagulate should
be based on the risk factors rather than the type of AF.3,5,17,18
However, none of these reports analysed the impact of AC on the
risk of major adverse events using a large prospective cohort, such
as GARFIELD-AF.
This registry provides further confirmation that the AF pattern
should not be taken into consideration when deciding on AC.
Indeed, there is a continuum of risk for stroke/SE across the different
patterns of AF. In patients with paroxysmal AF, the risk of stroke is
twice as high as in the general population.17 In paroxysmal AF
patients, the burden of AF (as defined by the percentage of time
spent in AF during long-term monitoring) is significantly and indepen-
dently associated with a higher risk of ischaemic stroke as shown by
Go et al.19 In other words, what matters is not AF pattern, but the
time spent in AF. The most recent Guidelines implicitly suggest that
the decision to anticoagulate should be based on the clinical risk pro-
file for stroke as assessed by various risk scoring systems/calculators,
such as CHA2DS2-VASc, and not AF pattern.
1,3,20 In other words,
also paroxysmal AF should be anticoagulated according to the
CHA2DS2-VASc assessment.
The differences in the risks of stroke/SE at 2-year follow-up,
though substantial across the AF patterns, were not captured by the
current scoring systems as in this population, the median values of
CHA2DS2-VASc score (and also HAS-BLED score) were similar irre-
spective of AF patterns. As recently proposed, employing biomarker
measurements, in addition to the clinical risk profile, may further re-
fine the predictive value of such risk calculators.21,22
Though the ability of CHA2DS2-VASc score to assess the risk of
stroke/SE is well established in this context, it was suggested that it
might benefit from the inclusion of other factors, including the type of
AF. As suggested previously, taking AF pattern into consideration
could aid the decision to anticoagulate, particularly in patients with a
low stroke risk, i.e. a CHA2DS2-VASc score of 2 or less.
13 This was
not confirmed in this report as the rate of events was too low to con-
duct meaningful sensitivity analyses in these patients.
GARFIELD-AF risk calculator, derived from GARFIELD-AF cohort
and externally validated on ORBIT-AF cohort, was shown to be a
better predictor of the risk of stroke/SE than CHA2DS2-VASc score
in patients with a high, intermediate, or low stroke risk.8 Using the
GARFIELD-AF risk calculator, which incorporates AF patterns in its
model, we were not able to show that type of AF was associated
with a higher estimated risk of stroke/SE or bleeding. The
GARFIELD-AF risk calculator showed a continuum of risk for death
as evidenced by a gradual increase in the risk score across all three
AF patterns. The risk of death is undoubtedly an important incentive
for ensuring the comprehensive management of patients, including
....................................................................................................................................................................................................................
Table 1 Continued
Paroxysmal
(N514 344)
Persistent
(N5 8064)
Permanent
(N56773)
P-value
Dementia 173 (1.2) 111 (1.4) 142 (2.1) <0.0001
Moderate-to-severe chronic renal disease 1347 (10.7) 809 (11.7) 901 (15.2) <0.0001
Smoking status, n (%) <0.0001
Never-smoker 8742 (67.1) 4756 (64.2) 4066 (64.1)
Ex-smoker 2864 (22.0) 1839 (24.8) 1727 (27.2)
Current smoker 1429 (11.0) 815 (11.0) 548 (8.6)
Alcohol consumption, n (%) <0.0001
Abstinent 6710 (55.3) 3687 (53.1) 3009 (51.2)
Light 3971 (32.7) 2311 (33.3) 2177 (37.0)
Moderate 1189 (9.8) 749 (10.8) 560 (9.5)
Heavy 260 (2.1) 194 (2.8) 131 (2.2)
CHA2DS2-VASc score, median (IQR) 3.0 (2.0; 4.0) 3.0 (2.0; 4.0) 3.0 (2.0; 4.0) <0.0001
CHA2DS2-VASc score, mean (SD) 3.1 (1.6) 3.1 (1.6) 3.5 (1.5)
HAS-BLED score, median (IQR)a 1.0 (1.0; 2.0) 1.0 (1.0; 2.0) 1.0 (1.0; 2.0) <0.0001
HAS-BLED score, mean (SD)a 1.4 (0.9) 1.4 (0.9) 1.5 (0.9)
GARFIELD death score, median (IQR) 1.8 (1.0; 3.4) 2.6 (1.4; 5.0) 3.3 (1.9; 5.8) <0.0001
GARFIELD death score, mean (SD) 2.9 (3.6) 4.3 (5.1) 4.9 (5.1)
GARFIELD stroke score, median (IQR) 0.9 (0.6; 1.4) 0.9 (0.6; 1.4) 1.0 (0.7; 1.6) <0.0001
GARFIELD stroke score, mean (SD) 1.2 (1.0) 1.2 (1.1) 1.4 (1.2)
GARFIELD bleeding score, median (IQR) 0.9 (0.6; 1.3) 0.9 (0.6; 1.3) 1.0 (0.8; 1.5) <0.0001
GARFIELD bleeding score, mean (SD) 1.0 (0.7) 1.1 (0.7) 1.2 (0.7)
BP, blood pressure; IQR, interquartile range; SD, standard deviation.
aThe risk factor ‘labile INRs’ is not included in the HAS-BLED score as it is not collected at baseline. As a result, the maximum HAS-BLED score at baseline is 8 points (not 9).
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Figure 1 Antithrombotic therapy at diagnosis according to type of AF. AF, atrial fibrillation; AP, antiplatelet; DTI, direct thrombin inhibitor; FXa,
factor Xa; VKA, vitamin K antagonist.
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Table 2 Incidence event rates per 100 person-years and corresponding 95% confidence intervals during 2-year follow-
up of patients with different types of AF
Outcomes Types of AF
Paroxysmal
(N5 14 344)
Persistent
(N5 8064)
Permanent
(N5 6773)
Overall
(N5 29 181)
Events Rates
(95% CI)
Events Rates
(95% CI)
Events Rates
(95% CI)
Events Rates
(95% CI)
Stroke/systemic embolism and its components
Stroke/systemic embolism 301 1.16 (1.03–1.29) 184 1.29 (1.1–1.49) 194 1.63 (1.42–1.88) 679 1.30 (1.21–1.40)
Stroke without systemic embolism 275 1.06 (0.94–1.19) 161 1.12 (0.96–1.31) 167 1.40 (1.20–1.63) 603 1.15 (1.06–1.25)
Ischaemic stroke 191 0.73 (0.63–0.84) 120 0.84 (0.70–1.00) 127 1.06 (0.89–1.26) 438 0.84 (0.76–0.92)
Ischaemic stroke or unknown type of stroke 246 0.94 (0.83–1.07) 148 1.03 (0.88–1.21) 149 1.25 (1.06–1.46) 543 1.04 (0.95–1.13)
Major bleeding and its components
Major bleeding 190 0.73 (0.63–0.84) 103 0.72 (0.59–0.87) 116 0.97 (0.81–1.16) 409 0.78 (0.71–0.86)
Major bleeding other than primary
haemorrhagic stroke
177 0.68 (0.58–0.79) 92 0.64 (0.52–0.78) 100 0.84 (0.69–1.02) 369 0.70 (0.63–0.78)
Mortality and its components
All-cause mortality 716 2.72 (2.53–2.93) 574 3.97 (3.65–4.30) 713 5.92 (5.50–6.37) 2003 3.79 (3.63–3.96)
Cardiovascular 259 0.99 (0.87–1.11) 214 1.48 (1.29–1.69) 282 2.34 (2.08–2.63) 755 1.43 (1.33–1.54)
Non-cardiovascular mortality 292 1.11 (0.99–1.25) 215 1.49 (1.30–1.70) 275 2.29 (2.03–2.57) 782 1.48 (1.38–1.59)
Myocardial infraction or acute
coronary syndrome
193 0.74 (0.64–0.85) 95 0.66 (0.54–0.81) 97 0.81 (0.66–0.99) 385 0.73 (0.66–0.81)
Congestive heart failure 390 1.51 (1.37–1.67) 331 2.35 (2.11–2.62) 302 2.58 (2.31–2.89) 1023 1.98 (1.87–2.11)
CI, confidence interval.
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the prescription of anticoagulants and the optimal management of
comorbidities that have a major impact on outcome, which is chiefly,
but not limited to, HF. In evaluations of all patients, regardless of risk,
AC was associated with a >30% risk reduction in death rates.23,24
Limitations
The current study has several limitations. The event rates are low in
this study, both ischaemic stroke and major bleeding. This raises the
concern that not all events have been identified.
The classification of AF at a single time point can be misleading as
AF patterns often change over time. Hence the one-time rhythm as-
sessment is a limitation. Furthermore, there was no type of AF deter-
mination during the 2-year follow-up period.
This is an observational database. Oral anticoagulant treatments
were not randomized. Although adjustments were made for
confounding, one cannot make conclusive statements about causa-
tion for AF type or treatment with outcomes.
The type of AF classification is a relatively poor surrogate mea-
sure for the burden of AF (proportion of time spent in AF).
Another difficulty is that patients with paroxysmal AF, in general,
are healthier than those with the non-self-limiting types of AF, al-
though our statistical methods have attempted to correct for such
differences. Finally, the reasons why individual patients/investiga-
tors choose not to use anticoagulants are complex and incom-
pletely understood.24
A further limitation pertains to the question whether results
from this registry are generalizable. Precautions have been made
that patients opting to be included in the GARFIELD-AF registry
are as representable as possible of a general AF population, yet
there remains an underlying selection that might introduce a bias.
For example, it is conceivable that patients agreeing to be followed
0.6
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Adjusted HR (95% CI)
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1.14 (0.94-1.37)
1.27 (1.05-1.53)
1 (ref.)
1.08 (0.89-1.32)
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1 (ref.)
0.91 (0.71-1.17)
0.91 (0.71-1.18)
1 (ref.)
1.23 (1.06-1.43)
1.24 (1.06-1.45)
1 (ref.)
0.91 (0.71-1.16)
1.01 (0.80-1.28)
1 (ref.)
1.38 (1.23-1.54)
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Figure 2 Adjusteda hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) during 2-years follow-up according to type of atrial fibril-
lation. The reference group is patients with paroxysmal AF. aHazard ratios were adjusted for age, gender, race, smoking, diabetes, hypertension,
stroke/transient ischaemic attack, history of bleeding, cardiac failure, vascular disease, moderate-to-severe chronic kidney disease, and anticoagulant
treatment at baseline. The model for major bleeding was furtherly adjusted for heavy alcohol consumption.
AF patterns, anticoagulation, and outcome 7
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/advance-article-abstract/doi/10.1093/europace/euz292/5634164 by St G
eorge's U
niversity of London user on 29 N
ovem
ber 2019
in a registry have a different level of interest in the disease studied,
which in turn might lead to certain more conscientious treatment
decisions.
In a sensitivity analysis comparing the excluded patients with
unavailable (new/unclassified) type of AF and the selected patients
with known type of AF, some differences emerged both in terms of
baseline characteristics and with regard to the event rates
(Supplementary material online, Tables S2 and S3).
Lastly, loss to follow-up could potentially be different across expo-
sure groups, since permanent AF patients may be associated with a
worse prognosis in general, irrespective of the outcomes investi-
gated, which in turn may lead to a higher drop-out of the registry.
Our analysis provided clear evidence that there was no significant dif-
ference in drop-out rates or lost-to-follow-up between the type of
AF groups (data not shown).
Conclusion
In non-anticoagulated patients, non-paroxysmal AF patterns were as-
sociated with significantly higher risks of death, stroke/SE, and new/
worsening CHF than paroxysmal AF pattern. In anticoagulated
patients, the risks of stroke/SE and new/worsening HF were similar
across all AF patterns, but non-paroxysmal AF patterns remained
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Congestive heart failure
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No anticoagulant treatment Anticoagulant treatment
0.0044
0.0013
0.0840
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Figure 3 Adjusteda hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for stroke or systemic embolism, ischaemic stroke, con-
gestive heart failure or all-cause mortality by type of AF, stratified by anticoagulant treatment at baseline. The reference group is patients with parox-
ysmal AF. aHazard ratios were adjusted for age, gender, race, smoking, diabetes, hypertension, stroke/transient ischaemic attack, history of bleeding,
cardiac failure, vascular disease, moderate-to-severe chronic kidney disease, and anticoagulant treatment at baseline.
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All-cause mortality
Paroxysmal
Persistent
Permanent
Paroxysmal
Persistent
Permanent
0.8 1.0 1.2
Adjusted HR Adjusted HR
No anticoagulant treatment Anticoagulant treatment
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Figure 4 Adjusteda hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for stroke or systemic embolism, ischaemic stroke, con-
gestive heart failure or all-cause mortality by type of AF, stratified by anticoagulant (AC) treatment at baseline in patients with CHA2DS2-VASc score
>_2. The reference group is patients with paroxysmal AF. aHazard ratios were adjusted for age, gender, race, smoking, diabetes, hypertension, stroke/
transient ischaemic attack, history of bleeding, cardiac failure, vascular disease, moderate-to-severe chronic kidney disease, and anticoagulant treat-
ment at baseline.
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associated with a significantly higher risk of death than paroxysmal AF
pattern. A continuum in the risk of death across all AF patterns was
shown by GARFIELD-AF risk score. Thus, AF pattern is no longer
prognostic for stroke/SE when patients are treated with
anticoagulants.’
Supplementary material
Supplementary material is available at Europace online.
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